8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Feb 23, 2026·SEC
GeneDx Holdings Corp.(WGS)Earnings, Financials & Key Ratios
WGS•NASDAQ
$34.71
$1.02B mkt cap·Price updated May 6, 2026
AboutGeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.Show more
- Revenue$428M+40.0%
- EBITDA$13M+1165.2%
- Net Income-$21M+59.8%
- EPS (Diluted)-0.73+62.4%
- Gross Margin69.74%+9.6%
- EBITDA Margin3.14%+861.1%
- Operating Margin-2.76%+63.7%
- Net Margin-4.92%+71.3%
- ROE-7.6%+65.6%
- ROIC-2.8%+57.8%
- Debt/Equity0.49+4.1%
- Interest Coverage-7.32+4.3%
WGS Key Insights
GeneDx Holdings Corp. (WGS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 38.6%
- ✓Strong Piotroski F-Score: 7/9
- ✓Strong 5Y sales CAGR of 19.0%
✗Weaknesses
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
WGS Price & Volume
GeneDx Holdings Corp. (WGS) stock price & volume — 10-year historical chart
Loading chart...
WGS Growth Metrics
GeneDx Holdings Corp. (WGS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years18.98%
3 Years22.13%
TTM34.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-101.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-84.72%
Return on Capital
10 Years-81.72%
5 Years-70.91%
3 Years-18.91%
Last Year-2.86%
WGS Recent Earnings
GeneDx Holdings Corp. (WGS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 4, 2026EPS
$0.28
Est $0.06
-366.7%
Revenue
$102M
Est $112M
-9.1%
Q1 2026
Feb 23, 2026EPS
$0.14
Est $0.11
+27.3%
Revenue
$121M
Est $120M
+0.6%
Q4 2025
Oct 28, 2025EPS
$0.49
Est $0.28
+75.0%
Revenue
$117M
Est $120M
-3.1%
Q3 2025
Jul 29, 2025EPS
$0.50
Est $0.10
+400.0%
Revenue
$103M
Est $99M
+4.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.28vs $0.06-366.7% | $102Mvs $112M-9.1% |
| Q1 2026 | Feb 23, 2026 | $0.14vs $0.11+27.3% | $121Mvs $120M+0.6% |
| Q4 2025 | Oct 28, 2025 | $0.49vs $0.28+75.0% | $117Mvs $120M-3.1% |
| Q3 2025 | Jul 29, 2025 | $0.50vs $0.10+400.0% | $103Mvs $99M+4.1% |
Based on last 12 quarters of dataView full earnings history →
WGS Peer Comparison
GeneDx Holdings Corp. (WGS) competitors in Life Sciences and Precision Medicine Software — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.23% | 0.16 |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.78% | 1.05 |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 3.34% | 0.06 |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 4.3% | 0.94 |
 BFLY | 1.19B | 4.55 | -14.68 | 18.96% | -73.63% | -36.79% | 0.10 | |
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 | |
 PGNY | 1.53B | 18.70 | 28.77 | 10.4% | 4.54% | 11.37% | 12.52% | 0.05 |
Compare WGS vs Peers
GeneDx Holdings Corp. (WGS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WGS Income Statement
GeneDx Holdings Corp. (WGS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 179.32M | 212.19M | 234.69M | 202.57M | 305.45M | 427.54M | 442.68M |
| Revenue Growth % | - | 18.33% | 10.6% | -13.69% | 50.79% | 39.97% | 34.09% |
| Cost of Goods Sold | 175.3M | 228.8M | 261.44M | 112.56M | 111.05M | 129.37M | 140.12M |
| COGS % of Revenue | 97.75% | 107.82% | 111.4% | 55.57% | 36.36% | 30.26% | - |
| Gross Profit | 4.03M▲ 0% | -16.6M▼ 512.4% | -26.75M▼ 61.1% | 90.01M▲ 436.5% | 194.4M▲ 116.0% | 298.17M▲ 53.4% | 302.56M▲ 0% |
| Gross Margin % | 2.25% | -7.82% | -11.4% | 44.43% | 63.64% | 69.74% | 68.35% |
| Gross Profit Growth % | - | -512.37% | -61.13% | 436.47% | 115.98% | 53.38% | - |
| Operating Expenses | 246.02M | 429.55M | 640.9M | 270.6M | 217.61M | 311.25M | 336.76M |
| OpEx % of Revenue | 137.19% | 202.43% | 273.08% | 133.59% | 71.24% | 72.8% | - |
| Selling, General & Admin | 163.93M | 318.73M | 338.24M | 194.71M | 168.48M | 239.22M | 263.37M |
| SG&A % of Revenue | 91.41% | 150.2% | 144.12% | 96.12% | 55.16% | 55.95% | - |
| Research & Development | 72.7M | 105.16M | 86.2M | 58.27M | 45.72M | 72.03M | 78.53M |
| R&D % of Revenue | 40.54% | 49.56% | 36.73% | 28.76% | 14.97% | 16.85% | - |
| Other Operating Expenses | 9.39M | 5.66M | 216.46M | 17.63M | 3.41M | 0 | -312K |
| Operating Income | -241.99M▲ 0% | -446.15M▼ 84.4% | -667.65M▼ 49.6% | -180.6M▲ 73.0% | -23.21M▲ 87.1% | -11.8M▲ 49.2% | -65.48M▲ 0% |
| Operating Margin % | -134.95% | -210.25% | -284.48% | -89.15% | -7.6% | -2.76% | -14.79% |
| Operating Income Growth % | - | -84.36% | -49.65% | 72.95% | 87.15% | 49.16% | - |
| EBITDA | -230.26M | -424.34M | -608.34M | -146.86M | -1.26M | 13.42M | -45.94M |
| EBITDA Margin % | -128.41% | -199.98% | -259.21% | -72.5% | -0.41% | 3.14% | -10.38% |
| EBITDA Growth % | - | -84.29% | -43.36% | 75.86% | 99.14% | 1165.24% | -654.84% |
| D&A (Non-Cash Add-back) | 11.73M | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M | 19.55M |
| EBIT | -238.87M | -242.56M | -457.51M | -170.19M | -23.21M | -18.6M | -13.16M |
| Net Interest Income | -1.97M | -2.76M | -666K | 1.11M | -3.03M | -2.54M | -1.9M |
| Interest Income | 506K | 79K | 2.54M | 1.11M | 0 | 0 | 0 |
| Interest Expense | 2.47M | 2.83M | 3.21M | 0 | 3.03M | 2.54M | 1.18M |
| Other Income/Expense | 654K | 200.76M | 69.62M | 3.9M | -29.42M | -9.34M | -11.99M |
| Pretax Income | -241.34M▲ 0% | -245.39M▼ 1.7% | -598.03M▼ 143.7% | -176.69M▲ 70.5% | -52.63M▲ 70.2% | -21.14M▲ 59.8% | -77.47M▲ 0% |
| Pretax Margin % | -134.58% | -115.64% | -254.81% | -87.23% | -17.23% | -4.94% | -17.5% |
| Income Tax | 0 | 0 | -49.05M | -926K | -343K | -116K | -1.46M |
| Effective Tax Rate % | 0% | 0% | 8.2% | 0.52% | 0.65% | 0.55% | 1.88% |
| Net Income | -241.34M▲ 0% | -245.39M▼ 1.7% | -548.98M▼ 123.7% | -175.77M▲ 68.0% | -52.29M▲ 70.3% | -21.02M▲ 59.8% | -77.81M▲ 0% |
| Net Margin % | -134.58% | -115.64% | -233.91% | -86.77% | -17.12% | -4.92% | -17.58% |
| Net Income Growth % | - | -1.68% | -123.72% | 67.98% | 70.25% | 59.8% | -101.7% |
| Net Income (Continuing) | -241.34M | -245.39M | -548.98M | -175.77M | -52.29M | -21.02M | -77.81M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -146.94▲ 0% | -74.93▲ 49.0% | -53.63▲ 28.4% | -7.23▲ 86.5% | -1.94▲ 73.2% | -0.73▲ 62.4% | -2.65▲ 0% |
| EPS Growth % | - | 49.01% | 28.43% | 86.52% | 73.17% | 62.37% | -84.72% |
| EPS (Basic) | -33.16 | -74.93 | -53.63 | -7.23 | -1.94 | -0.73 | - |
| Diluted Shares Outstanding | 5.63M | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M | 29.34M |
| Basic Shares Outstanding | 5.63M | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M | 29.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
WGS Balance Sheet
GeneDx Holdings Corp. (WGS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 174.11M | 483.54M | 212.62M | 182.34M | 197.97M | 268.29M | 270.63M |
| Cash & Short-Term Investments | 108.13M | 400.57M | 137.4M | 130.15M | 141.19M | 171.28M | 170.69M |
| Cash Only | 108.13M | 400.57M | 137.4M | 99.68M | 85.21M | 105M | 93.92M |
| Short-Term Investments | 0 | 0 | 0 | 30.47M | 55.97M | 66.28M | 76.76M |
| Accounts Receivable | 32.33M | 26.56M | 43.34M | 32.82M | 37.63M | 74.37M | 76.93M |
| Days Sales Outstanding | 65.81 | 45.69 | 67.41 | 59.13 | 44.97 | 63.49 | 53.65 |
| Inventory | 24.96M | 33.46M | 13.66M | 8.78M | 10.65M | 13.95M | 12.24M |
| Days Inventory Outstanding | 51.98 | 53.37 | 19.08 | 28.46 | 35 | 39.36 | 31.71 |
| Other Current Assets | 4.12M | 3.8M | 6.39M | 1.96M | 1.08M | 1.51M | 10.77M |
| Total Non-Current Assets | 77.53M | 70.55M | 332.64M | 236.42M | 221.41M | 301.9M | 235.67M |
| Property, Plant & Equipment | 63.11M | 62.72M | 84.28M | 59.38M | 58.51M | 69.11M | 84.78M |
| Fixed Asset Turnover | 2.84x | 3.38x | 2.78x | 3.41x | 5.22x | 6.19x | 6.20x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 13.52M | 1.64M |
| Intangible Assets | 0 | 0 | 186.65M | 172.63M | 158.6M | 168.48M | 144.97M |
| Long-Term Investments | 10.83M | 900K | 900K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.6M | 6.93M | 6.48M | 4.41M | 4.31M | 3.32M | 16.23M |
| Total Assets | 251.64M▲ 0% | 554.09M▲ 120.2% | 545.26M▼ 1.6% | 418.76M▼ 23.2% | 419.38M▲ 0.1% | 570.19M▲ 36.0% | 506.3M▲ 0% |
| Asset Turnover | 0.71x | 0.38x | 0.43x | 0.48x | 0.73x | 0.75x | 0.87x |
| Asset Growth % | - | 120.19% | -1.59% | -23.2% | 0.15% | 35.96% | 89.39% |
| Total Current Liabilities | 73.44M | 101.28M | 144.3M | 58.82M | 54.82M | 108.91M | 87.64M |
| Accounts Payable | 26.74M | 44.69M | 46.02M | 10.24M | 7.95M | 2.46M | 0 |
| Days Payables Outstanding | 55.67 | 71.3 | 64.24 | 33.2 | 26.14 | 6.94 | 5.61 |
| Short-Term Debt | 3.51M | 3.42M | 10.87M | 497K | 0 | 8.95M | 5.13M |
| Deferred Revenue (Current) | 1.78M | 473K | 40K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 41.42M | 52.7M | 67.08M | 30.88M | 30.42M | 67.86M | 82.51M |
| Current Ratio | 2.37x | 4.77x | 1.47x | 3.10x | 3.61x | 2.46x | 2.46x |
| Quick Ratio | 2.03x | 4.44x | 1.38x | 2.95x | 3.42x | 2.34x | 2.34x |
| Cash Conversion Cycle | 62.12 | 27.77 | 22.24 | 54.39 | 53.83 | 95.91 | 79.75 |
| Total Non-Current Liabilities | 173.81M | 64.71M | 147.26M | 131.92M | 119.32M | 153.1M | 164.54M |
| Long-Term Debt | 18.97M | 11M | 6.25M | 52.69M | 51.91M | 86.95M | 66.33M |
| Capital Lease Obligations | 20.78M | 18.43M | 60.01M | 62.94M | 60.92M | 56.05M | 172.82M |
| Deferred Tax Liabilities | 0 | 0 | 56.98M | 1.56M | 965K | 47.24M | 49.02M |
| Other Non-Current Liabilities | 134.06M | 35.28M | 24.02M | 14.73M | 5.52M | -37.14M | 68.6M |
| Total Liabilities | 247.25M | 165.99M | 291.56M | 190.74M | 174.13M | 262.01M | 252.18M |
| Total Debt | 43.26M | 32.85M | 77.13M | 119.77M | 116.17M | 151.95M | 71.46M |
| Net Debt | -64.88M | -367.72M | -60.27M | 20.09M | 30.96M | 46.95M | -22.46M |
| Debt / Equity | 9.86x | 0.08x | 0.30x | 0.53x | 0.47x | 0.49x | 0.49x |
| Debt / EBITDA | - | - | - | - | - | 11.32x | -1.56x |
| Net Debt / EBITDA | - | - | - | - | - | 3.50x | 3.50x |
| Interest Coverage | -96.55x | -85.56x | -142.66x | - | -7.66x | -7.32x | -11.13x |
| Total Equity | 4.39M▲ 0% | 388.1M▲ 8744.6% | 253.71M▼ 34.6% | 228.02M▼ 10.1% | 245.25M▲ 7.6% | 308.18M▲ 25.7% | 254.12M▲ 0% |
| Equity Growth % | - | 8744.64% | -34.63% | -10.13% | 7.56% | 25.66% | 110.12% |
| Book Value per Share | 0.78 | 118.50 | 24.78 | 9.38 | 9.12 | 11.46 | 8.66 |
| Total Shareholders' Equity | 4.39M | 388.1M | 253.71M | 228.02M | 245.25M | 308.18M | 254.12M |
| Common Stock | 0 | 24K | 38K | 2K | 2K | 3K | 3K |
| Retained Earnings | -330.05M | -575.44M | -1.12B | -1.3B | -1.35B | -1.37B | -1.44B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 425K | 830K | 936K | 683K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WGS Cash Flow Statement
GeneDx Holdings Corp. (WGS) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -93.13M | -190.43M | -319.15M | -180.15M | -28.5M | 33.28M | 33.28M |
| Operating CF Margin % | -51.93% | -89.74% | -135.99% | -88.93% | -9.33% | 7.78% | - |
| Operating CF Growth % | - | -104.49% | -67.59% | 43.55% | 84.18% | 216.78% | 374.68% |
| Net Income | -241.34M | -245.39M | -548.98M | -175.77M | -52.29M | -21.02M | -77.81M |
| Depreciation & Amortization | 11.73M | 21.81M | 59.31M | 35.83M | 21.95M | 25.22M | 26.36M |
| Stock-Based Compensation | 120.23M | 219.42M | 41.98M | -326K | 9.14M | 32.16M | 37.17M |
| Deferred Taxes | 0 | 0 | -49.12M | -926K | -343K | 0 | 450K |
| Other Non-Cash Items | 2.4M | -194.35M | 141.53M | -721K | 17.79M | 12.51M | 23.46M |
| Working Capital Changes | 13.85M | 8.08M | 36.13M | -38.24M | -24.75M | -15.6M | -18.95M |
| Change in Receivables | -10.61M | 5.54M | 5.53M | 10.26M | -5.42M | -36.23M | -30.23M |
| Change in Inventory | -8.98M | -10.62M | 4.6M | 975K | -2.58M | -3.44M | 285K |
| Change in Payables | 0 | 0 | 34.46M | -46.95M | -20.46M | 12.1M | -6.25M |
| Cash from Investing | -31.97M | -20.79M | -141.33M | -43.73M | -30.13M | -61.52M | -69.36M |
| Capital Expenditures | -24.09M | -9.4M | -14.32M | -5.71M | -5.49M | -19.02M | -19.34M |
| CapEx % of Revenue | 13.44% | 4.43% | 6.1% | 2.82% | 1.8% | 4.45% | - |
| Acquisitions | 0 | 0 | -127M | -8.11M | 0 | -32.86M | -32.86M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -7.88M | -11.39M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 129.06M | 493.73M | 197.31M | 186.24M | 44.16M | 48.02M | 72.9M |
| Debt Issued (Net) | 11.73M | -13.47M | -3.29M | 42.95M | -3.23M | -3.66M | 911K |
| Equity Issued (Net) | 117.32M | 442.68M | 197.66M | 143M | 46.5M | 51.69M | -14.63M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 64.51M | 2.95M | 285K | 891K | 0 | 86.61M |
| Net Change in Cash | 3.95M▲ 0% | 282.51M▲ 7044.9% | -263.17M▼ 193.2% | -37.72M▲ 85.7% | -14.47M▲ 61.7% | 19.79M▲ 236.8% | -5.78M▲ 0% |
| Free Cash Flow | -125.1M▲ 0% | -211.22M▼ 68.8% | -333.48M▼ 57.9% | -185.86M▲ 44.3% | -33.99M▲ 81.7% | 14.26M▲ 142.0% | -28.65M▲ 0% |
| FCF Margin % | -69.76% | -99.54% | -142.09% | -91.75% | -11.13% | 3.34% | -6.47% |
| FCF Growth % | - | -68.84% | -57.88% | 44.27% | 81.71% | 141.96% | -119.09% |
| FCF per Share | -22.23 | -64.49 | -32.58 | -7.64 | -1.26 | 0.53 | 0.53 |
| FCF Conversion (FCF/Net Income) | 0.39x | 0.78x | 0.58x | 1.02x | 0.55x | -1.58x | 0.37x |
| Interest Paid | 1.75M | 2.75M | 1.93M | 3.04M | 6.68M | 0 | -1.6M |
| Taxes Paid | 0 | 349K | 1.24M | 1.47M | 1.17M | 0 | -206K |
WGS Key Ratios
GeneDx Holdings Corp. (WGS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -125.04% | -171.07% | -72.97% | -22.1% | -7.6% | -27.5% |
| Return on Invested Capital (ROIC) | - | -468.38% | -61.35% | -6.64% | -2.8% | -2.8% |
| Gross Margin | -7.82% | -11.4% | 44.43% | 63.64% | 69.74% | 68.35% |
| Net Margin | -115.64% | -233.91% | -86.77% | -17.12% | -4.92% | -17.58% |
| Debt / Equity | 0.08x | 0.30x | 0.53x | 0.47x | 0.49x | 0.49x |
| Interest Coverage | -85.56x | -142.66x | - | -7.66x | -7.32x | -11.13x |
| FCF Conversion | 0.78x | 0.58x | 1.02x | 0.55x | -1.58x | 0.37x |
| Revenue Growth | 18.33% | 10.6% | -13.69% | 50.79% | 39.97% | 34.09% |
WGS SEC Filings & Documents
GeneDx Holdings Corp. (WGS) SEC filings — annual & quarterly reports (10-K, 10-Q)
WGS Frequently Asked Questions
GeneDx Holdings Corp. (WGS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
GeneDx Holdings Corp. (WGS) reported $442.7M in revenue for fiscal year 2025. This represents a 147% increase from $179.3M in 2020.
GeneDx Holdings Corp. (WGS) grew revenue by 40.0% over the past year. This is strong growth.
GeneDx Holdings Corp. (WGS) reported a net loss of $77.8M for fiscal year 2025.
Dividend & Returns
GeneDx Holdings Corp. (WGS) has a return on equity (ROE) of -7.6%. Negative ROE indicates the company is unprofitable.
GeneDx Holdings Corp. (WGS) had negative free cash flow of $28.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More WGS
GeneDx Holdings Corp. (WGS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates